Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.
Histology
Mesothelioma
Surgery
Systemic treatment
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
13
08
2019
revised:
19
01
2020
accepted:
20
01
2020
pubmed:
14
3
2020
medline:
7
1
2021
entrez:
14
3
2020
Statut:
ppublish
Résumé
Histologic subtypes of malignant pleural mesothelioma are a major prognostic indicator and decision denominator for all therapeutic strategies. In an ambiguous case, a rare transitional mesothelioma (TM) pattern may be diagnosed by pathologists either as epithelioid mesothelioma (EM), biphasic mesothelioma (BM), or sarcomatoid mesothelioma (SM). This study aimed to better characterize the TM subtype from a histological, immunohistochemical, and molecular standpoint. Deep learning of pathologic slides was applied to this cohort. A random selection of 49 representative digitalized sections from surgical biopsies of TM was reviewed by 16 panelists. We evaluated BAP1 expression and CDKN2A (p16) homozygous deletion. We conducted a comprehensive, integrated, transcriptomic analysis. An unsupervised deep learning algorithm was trained to classify tumors. The 16 panelists recorded 784 diagnoses on the 49 cases. Even though a Kappa value of 0.42 is moderate, the presence of a TM component was diagnosed in 51%. In 49% of the histological evaluation, the reviewers classified the lesion as EM in 53%, SM in 33%, or BM in 14%. Median survival was 6.7 months. Loss of BAP1 observed in 44% was less frequent in TM than in EM and BM. p16 homozygous deletion was higher in TM (73%), followed by BM (63%) and SM (46%). RNA sequencing unsupervised clustering analysis revealed that TM grouped together and were closer to SM than to EM. Deep learning analysis achieved 94% accuracy for TM identification. These results revealed that the TM pattern should be classified as non-EM or at minimum as a subgroup of the SM type.
Identifiants
pubmed: 32165206
pii: S1556-0864(20)30174-X
doi: 10.1016/j.jtho.2020.01.025
pmc: PMC8864581
mid: NIHMS1723349
pii:
doi:
Substances chimiques
BAP1 protein, human
0
Tumor Suppressor Proteins
0
Ubiquitin Thiolesterase
EC 3.4.19.12
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1037-1053Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
Nat Med. 2019 Oct;25(10):1519-1525
pubmed: 31591589
Ann Diagn Pathol. 2017 Feb;26:31-37
pubmed: 28038708
Am J Surg Pathol. 2016 May;40(5):714-8
pubmed: 26900815
J Thorac Oncol. 2016 Feb;11(2):142-54
pubmed: 26811225
J Thorac Oncol. 2018 Aug;13(8):1189-1203
pubmed: 29723687
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
J Thorac Oncol. 2018 May;13(5):606-623
pubmed: 29524617
Lung Cancer. 2018 Oct;124:95-101
pubmed: 30268487
Arch Pathol Lab Med. 2013 May;137(5):632-6
pubmed: 23627453
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867
Int J Clin Oncol. 2016 Jun;21(3):523-30
pubmed: 26577445
Pathol Int. 2008 Feb;58(2):75-83
pubmed: 18199156
J Thorac Oncol. 2015 Nov;10(11):1634-41
pubmed: 26317916
JAMA. 2018 Sep 18;320(11):1101-1102
pubmed: 30178065
Lancet Oncol. 2015 Dec;16(16):1651-8
pubmed: 26538423
Hum Pathol. 2017 Sep;67:160-168
pubmed: 28782639
Arch Pathol Lab Med. 2020 Apr;144(4):446-456
pubmed: 31389715
Arch Pathol Lab Med. 2018 Jan;142(1):89-108
pubmed: 28686500
EBioMedicine. 2019 Oct;48:191-202
pubmed: 31648983
Am J Surg Pathol. 2017 Sep;41(9):1221-1225
pubmed: 28614203
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Hum Pathol. 2015 Nov;46(11):1670-8
pubmed: 26376834
Mod Pathol. 2010 Mar;23(3):470-9
pubmed: 20081811
Med Oncol. 2018 May 29;35(7):98
pubmed: 29845408
Mod Pathol. 2018 Apr;31(4):598-606
pubmed: 29327706
Arch Pathol Lab Med. 2016 Oct;140(10):1104-10
pubmed: 27031777
Am J Surg Pathol. 2015 Jul;39(7):977-82
pubmed: 25634745
Eur J Cancer. 2016 Apr;57:104-11
pubmed: 26916546
Arch Pathol Lab Med. 2018 Dec;142(12):1549-1553
pubmed: 30059257
Ultrastruct Pathol. 2009 Mar-Apr;33(2):52-60
pubmed: 19274581
J Thorac Oncol. 2018 Nov;13(11):1655-1667
pubmed: 30266660
Histopathology. 2000 Sep;37(3):224-31
pubmed: 10971698
Neural Comput. 2012 Aug;24(8):1967-2006
pubmed: 22509963
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Histopathology. 2009 May;54(6):667-76
pubmed: 19438742
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571